Cannabis: WHO just acknowledged historical misjudgment and heads towards global policy update

After thoroughly assessing Cannabis, THC and CBD in June, the WHO has just recognized its historical misjudgment that led to the placement of Cannabis medicines among heroin or fentanyl derivates, and will consider an international change of scheduling to adequate policies with evidence. #ECDD40

40th ECDD meeting in Geneva: pivotal moment for global Cannabis policies.

This week in Geneva for the first time ever, the WHO drugs committee has heard the voices of doctors, patients, and researchers, and started to weigh the harms and benefits of Cannabis neutrally.

Crimson paper #3. The review(s).

Pre & Critical reviews: insights into the processes of the WHO scientific abuse liability assessment for drugs.

Cannabis review by the WHO: all you need to know

In 2018 for the first time, the World Health Organization is assessing the medical uses and harms of Cannabis, and will recommend the suitable classification to be applied internationally. We promote an objective and independent assessment, that recognizes and acknowledges modern research on Cannabis. Support us!

Major shift in global drug policies: the Human Rights Council catches up with the Commission on Narcotic Drugs

Last month, the main UN body on drugs self-disqualified, leaving room for UN Human Rights organs to increase influence over global drug policies.

Crimson paper #2. The committee.

The crimson papers are a series of short documents aimed at sharing knowledge regarding the process of scheduling plants, medicines and substances within the international drug control treaty framework.

Pin It on Pinterest